Editing Prostate Cancer: Prevention (section)

=== <span style="color:#ff00ff">REDUCE (NEJM 2010)</span> ===
* '''<span style="color:#ff0000">Objective: determine whether a 5-ARI could reduce the risk of prostate cancer</span>'''
* '''<span style="color:#ff0000">Population: 8,231 men aged 50-75 with a negative prior biopsy within 6 months of enrollment baseline PSA 2.5-10, prostate volume ≤80cc</span>''' 
* '''<span style="color:#ff0000">Randomized to dutasteride vs. placebo daily</span>'''
* '''<span style="color:#ff0000">Primary end point: prevalence of cancer on study-mandated 10-core prostate biopsies performed at 2 and 4 years after randomization (different from PCPT where biopsy was not mandated)</span>'''
* '''<span style="color:#ff0000">Results:</span>''' 
**6.726 (82.6%) underwent at least one biopsy
** <span style="color:#ff0000">'''Significantly reduced risk of incident prostate cancer with dutasteride''' </span>
***'''Absolute risk reduction: 5%''' (19.9% dutasteride vs. 25.1% placebo)
** '''No difference in Gleason 7-10 cancers throughout the study, however, increased risk of Gleason 8-10 cancers during years 3 and 4 in dutasteride arm[https://www.nejm.org/doi/full/10.1056/NEJMoa0908127#]'''
* [https://www.nejm.org/doi/full/10.1056/NEJMoa0908127 Andriole, Gerald L., et al.] "Effect of dutasteride on the risk of prostate cancer." New England Journal of Medicine 362.13 (2010): 1192-1202.